Literature DB >> 9652633

Hepatitis C.

A M Di Bisceglie1.   

Abstract

Mesh：

Year:  1998        PMID： 9652633     DOI： 10.1016/S0140-6736(97)07361-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  62 in total

1.  Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?

Authors:  V D Hope; A Judd; M Hickman; T Lamagni; G Hunter; G V Stimson; S Jones; L Donovan; J V Parry; O N Gill
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

2.  Trends in deaths from malignant neoplasia of liver are poor indicator of hepatitis C infection.

Authors:  H E Harris; M E Ramsay; K Balogun; G J Alexander
Journal:  BMJ       Date:  1999-03-20

3.  Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain.

Authors:  D R Taylor; B Tian; P R Romano; A G Hinnebusch; M M Lai; M B Mathews
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

5.  Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect.

Authors:  Tatsuo Kanda; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif.

Authors:  Björn Schwer; Shaotang Ren; Thomas Pietschmann; Jürgen Kartenbeck; Katrin Kaehlcke; Ralf Bartenschlager; T S Benedict Yen; Melanie Ott
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

7.  Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.

Authors:  Hui Li; Brian J McMahon; Susan McArdle; Dana Bruden; Daniel G Sullivan; Dave Shelton; Heike Deubner; David R Gretch
Journal:  Virology       Date:  2008-03-17       Impact factor: 3.616

8.  Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.

Authors:  Hideyuki Suzuki; Hitoshi Takagi; Naondo Sohara; Daisuke Kanda; Satoru Kakizaki; Ken Sato; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

9.  Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups.

Authors:  Annunziata Faustini; Paola Colais; Emanuele Fabrizi; Anna Maria Bargagli; Marina Davoli; Domenico Di Lallo; Anteo Di Napoli; Patrizio Pezzotti; Chiara Sorge; Rita Grillo; Carla Maresca; Olga Recchia; Carlo A Perucci
Journal:  BMC Infect Dis       Date:  2010-04-19       Impact factor: 3.090

10.  Clinical significance of antibody to hepatitis B core antigen in multitransfused hemodialysis patients.

Authors:  Doaa M Elghannam; Rabab M Aly; Enas F Goda; Ehab E Eltoraby; Raghda E Farag
Journal:  Asian J Transfus Sci       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.